Ali Keshavarzian

Seed Amplification Assay-Based Detection of Alpha-Synuclein Aggregates Outperforms Immunohistochemical Analysis in the Intestinal Mucosal Biopsies of Parkinson's Disease and Multiple System Atrophy Participants

This study compares a seed amplification assay for alpha-synuclein aggregates with immunohistochemistry in intestinal biopsies of Parkinson's disease and multiple system atrophy patients, finding the assay detects aggregates more frequently and with higher specificity.

Senescence-associated loss of intestinal α1,2-fucose disrupts a modifiable host-microbiome homeostasis axis in people with HIV

This study identifies loss of intestinal 1,2-fucose in HIV-treated individuals as a modifiable host-microbiome mechanism linked to inflammation, barrier dysfunction, and aging.

Machine learning-based gut microbiota pattern and response to fiber as a diagnostic tool for chronic inflammatory diseases

This study uses machine learning to classify chronic inflammatory diseases based on gut microbiota patterns and response to fiber, achieving up to 95% accuracy in distinguishing between conditions with overlapping dysbiosis.

Sexually dimorphic responses to MPTP found in microglia, inflammation and gut microbiota in a progressive monkey model of Parkinson's disease

This study investigates sex differences in inflammatory responses and gut microbiota in a progressive monkey model of Parkinson's disease following MPTP treatment.

Gut bacterial tyrosine decarboxylases restrict the bioavailability of levodopa, the primary treatment in Parkinson’s disease

This study shows gut bacteria convert L-DOPA to dopamine, reducing its bioavailability and explaining variable dosing needs in Parkinson’s patients.